Lupus Nephritis: The Importance of Active Surveillance, Early Diagnoses, and Successful Treatment
This Exhibitor Spotlight presentation focuses on improving outcomes for patients with lupus nephritis (LN). It reviews the epidemiology of LN and the latest evidence and guideline recommendations for screening and treatment of the disease. Recently published guidelines for LN recommend active surveillance of patients with systemic lupus erythematosus every 3 months—particularly in patients at high risk for kidney involvement—in order to biopsy and classify LN in a timely manner. A recent review of current clinical practice shows that active surveillance for LN in patients with systemic lupus erythematosus may not be routinely conducted.
The guidelines also provide specific treatment targets at 3, 6, and 12 months based on evidence that achieving a complete response to therapy and attaining an early decrease in proteinuria are associated with improved kidney outcomes. Lastly, the presentation will highlight considerations and strategies to reduce cumulative glucocorticoid exposure in patients with LN.
We hope you will join us. Sponsored by Aurinia Pharma U.S., Inc.